“…Higher rates of recurrence and death are observed in women with micrometastases compared with women with negative lymph nodes; these assessments, coupled with quantification of metastatic burden, are a clinically relevant predictor of non‐SLN metastasis 8, 9, 10, 11, 12, 13. This type of assessment, however, has been the subject of great debate, because there are no differences in prognosis between women with micrometastases and those with ITC 14, 15, 16, 17, 18, 19, 20, 21…”